Theravance Biopharma Company Profile (NASDAQ:TBPH)

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.14) by $0.13. The company had revenue of $3.09 million for the quarter, compared to analysts' expectations of $5.07 million. Theravance Biopharma had a negative return on equity of 61.09% and a negative net margin of 358.95%. View Theravance Biopharma's Earnings History.

7 analysts have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $24.00 to $47.00. On average, they expect Theravance Biopharma's stock price to reach $39.83 in the next year. View Analyst Ratings for Theravance Biopharma.

Here are some recent quotes from research analysts about Theravance Biopharma stock:

• 1. Needham & Company LLC analysts commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected milestones in 2017. Results from Phase 1b TD-1473 trial in Ulcerative Colitis in mid-2017 are of particular interest, given size of market and differentiated mechanism (GI-restricted JAK inhibitor). We are favorably inclined. A second distinct JAK inhibitor, TD-3504 (GIrestricted tofacitinib prodrug), is expected to enter Phase 1 testing in 1H17 as a backup option. Other events include NDA submission for revefenacin in Chronic Obstructive Pulmonary Disease w/ collaborator Mylan, potential FDA approval of Closed Triple by collaborator GSK, as well as results from Phase 2 trials of TD-9855 in Neurogenic Orthostatic Hypotension and velusetrag in Gastroparesis." (2/28/2017)
• 2. According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Outperform rating for Theravance’s stock. Stronger than expected Vibativ sales driven by a combination of new indication and expansion of dedicated sales force. Sales of Vibativ increased by 62% QoQ and 152% YoY apparently driven by the expansion of the sales force from 6 to 50 reps in 4Q15 and the opportunity presented by the expanded label. Mgmt believes the growth in revenue will continue driven by the expansion of accounts and positive physician perception in using Vibativ in difficult to treat patients. Several catalysts in next 12 months could potentially add additional value to the company. As highlighted in our earlier note [LINK], our sum of the parts analysis identified potential 20% and 70% upside by end of 2016 and 2017, respectively." (8/9/2016)

Theravance Biopharma saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 6,119,351 shares, an increase of 12.6% from the April 13th total of 5,435,880 shares. Based on an average daily volume of 229,782 shares, the days-to-cover ratio is currently 26.6 days.

Some companies that are related to Theravance Biopharma include Galapagos NV (GLPG), Opko Health (OPK), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE), Nektar Therapeutics (NKTR), China Biologic Products (CBPO), Intercept Pharmaceuticals (ICPT), Intrexon Corp (XON), Puma Biotechnology (PBYI), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Clovis Oncology (CLVS), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Axovant Sciences Ltd (AXON), Portola Pharmaceuticals (PTLA) and Prothena Co. PLC (PRTA).

Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (20.25%), BlackRock Inc. (6.65%), Vanguard Group Inc. (5.83%), First Manhattan Co. (1.97%), State Street Corp (1.69%) and MARSHALL WACE ASIA Ltd (1.12%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Point72 Asset Management L.P., Morgan Stanley, Chescapmanager LLC, JPMorgan Chase & Co., Bank of America Corp DE, First Trust Advisors LP and SG Americas Securities LLC. Company insiders that have sold Theravance Biopharma stock in the last year include Bradford J Shafer and Brett K Haumann. View Insider Buying and Selling for Theravance Biopharma.

Theravance Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Goldman Sachs Group Inc., Woodford Investment Management Ltd, Vanguard Group Inc., Old West Investment Management LLC and Driehaus Capital Management LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Theravance Biopharma stock can currently be purchased for approximately $36.89.